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(57) ABSTRACT 
Lentiviral-based retrovirus vectors and an in vivo mutation 
rate assay employing them. More particularly, an assay for 
directly determining the in vivo mutation rate of HIV-1. 
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RETROVIRAL VECTOR AND CELL-BASED ASSAY 

FOR MEASURING THE MUTATIONS RATE OF 

RETROVIRUSES EMPLOYING SAME 

[0001] The present invention is directed toward a cell­
based assay that allows direct measurement of the mutation 
rate of retroviruses during replication. The assay employs a 
novellentivirus-based retroviral vector which is replication 
defective but transduction and infection competent. More 
particularly, the assay may be used to calculate the mutation 
frequency and mutation rate of HIV-1. 
[0002] Over twenty years into the ever-worsening AIDS 
pandemic, genetic variation remains the greatest obstacle for 
treating and preventing HIV-1 infection. To date, there are 
no assays that directly measure the mutation rate of HIV-1 
during replication in cell culture. There is an established 
need in the art for a phenotypic cell-based test for directly 
measuring the mutation rate of HIV-1. 
[0003] A high degree of genetic variation is associated 
with retroviruses in general and HIV-1 in particular, during 
the course of infection. This variation enables the virus to 
escape the host immune response, use multiple cell surface 
proteins for viral entry, mount resistance to antiretroviral 
drugs, and prevent effective vaccination. The polymerase 
enzymes responsible for replicating the HIV-1 genome are 
host cell DNA-dependent DNA polymerase, host cell RNA 
polymerase II, and the virally-encoded reverse transcriptase 
enzyme (RT). The host cell DNA-dependent DNA poly­
merase replicates the integrated provirus during cellular 
proliferation; it is not a mutation-prone polymerase and has 
a negligible contribution to the high mutation rate during 
HIV-1 replication. The host cell RNA polymerase II is 
responsible for transcription of the integrated provirus. To 
date, an accurate measurement of the RNA polymerase II 
mutation rate has not been reported. However, evidence 
suggests that RNA polymerase II has proofreading capabil­
ity, diminishing its reputed role in HIV-1 mutation. Reverse 
transcriptase (RT) copies the single-stranded RNA genome 
into a double-stranded DNA molecule. The RT enzyme is 
notoriously error-prone; its mutation rate is several orders of 
magnitude higher than DNA polymerases, due mainly to the 
lack of an associated 3'---;.5' exonuclease activity. Conse­
quently, RT is considered to be the principal contributor to 
HIV-1 genetic variation. 
[0004] Early in the AIDS epidemic, measurements of the 
HIV-1 mutation rate were performed in cell-free studies 
using artificial templates and purified enzyme and substrates 
(hereafter referred to as in vitro studies). These in vitro 
studies predicted the mutation rate for HIV-1 to be on the 
order of 1o-4 mutations per base per replication cycle. Other 
in vitro studies followed these initial reports using various 
assays to characterize the types of mutations such as base 
substitutions, insertions, and deletions that are associated 
with the high RT mutation rate. In vitro systems, however, 
may not accurately duplicate the physiologic conditions of a 
replicating virus. For example, retroviral mutations rates are 
higher in vitro as compared to rates measured during repli­
cation of the virus in cells (hereafter referred to as in vivo). 
Other researchers have shown that in vitro systems can 
generate reverse transcription products that are not naturally 
found in vivo, such as extended minus-strand strong stop 
DNA and non-templated base additions. 
[0005] In 1995, Mansky and Temin, (J. Viral. 689:5087-94 
(1995)), reported the development of an in vivo assay for 
measuring the mutation rate of HIV-1. The Mansky assay, 
however, measures the mutation rate indirectly and has 
several major drawbacks. The assay is indirect because it 
does not detect mutant proviruses in the target cell. Instead, 
the mutational target sequence, the lacZa peptide gene, is 
excised from the provirus and introduced into a bacterial 
system, where the mutational screening actually takes place. 
The screening is based on visual blue/white color selection 
of bacterial colonies on agar plates. This color selection is 
not an all-or-none effect. That is, there are many interme­
diate shades ofblue, creating a subjective mutation detection 
process. The lacZa peptide gene is isolated from a sea of 
pooled target cell genomic DNA by binding to a Lac 
repressor protein and recovery on nitrocellulose. This 
method is very labor intensive. Furthermore, the Lac repres­
sor protein is not readily available and typically must be 
custom-made. The reference assay is also indirect because 
colonies on the target cell dishes are pooled after the single 
cycle of viral replication. This pooling step results in a 
sampling type of measurement as opposed to a direct 
measurement. There is no way to know whether mutants are 
independent, potentially skewing the results on the types of 
mutations observed in this system. Because the cells are 
pooled, there is also no way to know the total number of 
viruses screened or number of mutant viruses detected. The 
lacZa peptide gene is small (280 bp) and the viral titers in the 
reference assay are low. These two features decrease the 
frequency by which mutants are detected and increase the 
number of infections that must be performed, thus increas­
ing cost. In fact, in order to achieve sufficient viral titers, the 
reference assay relies on co-cultivation of mitomycin­
treated virus-producing cells with target cells. Therefore, the 
vast majority of viral infections are forced cell-to-cell as 
opposed to infections by cell-free virus particles. The last 
major drawback of this assay is that it has not been made 
readily available to other researchers for independent veri­
fication and scientific study. 
[0006] Hence, there is a need in the art for a more 
economic, less-labor intensive, improved, readily available 
and independent cell-based assay to directly and more 
accurately measure the mutation rate of retroviruses, and, in 
particular, HIV-1. 
[0007] Accordingly, embodiments ofthe present invention 
are designed to provide a mutation rate assay that overcomes 
one or more of the deficiencies discussed above. 
[0008] In a broad vector embodiment, a lentivirus-based 
retroviral vector is provided wherein the vector comprises: 
at least a portion of a lentivirus genome; a disrupted gag and 
a disrupted pol gene such that the vector is rendered repli­
cation-defective; a disrupted env gene; and a mutational 
cassette, wherein the mutational cassette comprises 
sequences encoding: a mutation target promoter sequence; a 
genomic source comprising a mutation target gene wherein 
there is a number of base pairs in the mutation target gene; 
an internal ribosome entry site for expression of a selectable 
marker; and a selectable marker gene. 
[0009] In more specific embodiments, the lentivirus 
genome is selected from a group of retroviruses including 
human immunodeficiency virus type 1. In other specific 
embodiments the selectable marker comprises a hygromycin 
B resistance gene, the mutation target promoter comprises a 
human cytomegalovirus promoter, the mutation target may 
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comprise a thymidine kinase gene, and the genomic source 
comprising a mutation target gene may comprise a human 
herpes virus type 1 gene. Another aspect of the invention is 
directed to a cell comprising the inventive lentivirus. 
[0010] Another embodiment of the invention is directed to 
an assay for determining mutation frequency and mutation 
rate of a retrovirus. The assay comprises: a) constructing a 
pertinent embodiment of the inventive vector; b) stably 
transfecting cells from a cell culture with the vector from (a) 
wherein the cell culture is negative for the mutation target 
gene; c) placing the cells under selection with a medium 
selectable for the selectable marker to produce a quantity of 
cell clones which contain an integrated vector; d) transiently 
transfecting the quantity of cell clones with a set of helper 
plasmids to produce a vector virus, wherein the set of helper 
plasmids contain a complement of structural genes which 
permit replication; e) infecting naive cells from a cell culture 
with the vector virus; f) placing the cells from (e) under 
selection with the medium selectable for the selectable 
marker; g) cloning the cells from (f) to produce a quantity of 
initiator cell clones, wherein each of the quantity of cell 
clones is designated as an Initiator Clone (IC); h) confirming 
that the mutation target gene is functional in each IC and 
sequencing the mutation target gene for later comparison to 
mutation target genes which have undergone a cycle of 
replication; i) transiently transfecting the ICs with a set of 
helper plasmids to produce a vector virus; j) infecting naive 
cells from a target cell culture with the vector virus from (i) 
to produce a quantity of infected target cells; k) placing a 
first portion of the quantity of infected target cells under 
selection with the medium selectable for the selectable 
marker, placing a substantially similar second portion of the 
quantity of infected target cells under selection with the 
medium selectable for the selectable marker plus a selective 
medium for the mutation target gene; and I) determining a 
viral titer for the first portion and a viral titer for the second 
portion by counting drug-resistant quantities, wherein the 
mutation frequency is calculated by dividing the viral titer of 
the second portion by the viral titer of the first portion, and 
the mutation rate is calculated by dividing the mutation 
frequency by the number ofbase pairs in the mutation target 
gene. 
[0011] In specific embodiments the retrovirus is selected 
from the group consisting of, inter alia, human immunode­
ficiency virus type 1. In further specific embodiments the 
selectable marker gene may comprise a hygromycin B 
resistance gene, the medium selectable for the selectable 
marker may comprise hygromycin B, the mutation target 
gene may comprise thymine kinase, and the medium select­
able for the mutation target gene may comprise bromode­
oxyyuridine. 
[0012] Embodiments of the novel assay have one or more 
advantages and/or improvements over other known in vivo 
mutation rate assays. It is easier, more economical, and 
faster to perform. It provides a direct measurement of the 
mutation rate during a single cycle of viral replication, a 
known number ofmutants detected, and a known number of 
viruses screened. The inventive assay incorporates a larger 
target sequence that yields higher mutation frequencies and 
uses a natural viral infection process (as opposed to forced 
cell-to-cell infection). The present assay also has the poten­
tial for mechanization. 
[0013] The present retroviral vector and assay are addi­
tionally advantageous in the field of personalized medicine 
because they provide the potential for individualized moni­
toring of drug regimens in HIV-infected patients and for 
monitoring the development of drug resistance in infected 
individuals as well as across infected populations. The 
resultant target cells containing mutant proviruses that sur­
vive the drug selection process and may be propagated for 
further analysis. The vector and assay may be employed to 
study genetic variation of retroviruses including HIV-1. 
[0014] Embodiments of the assay described herein are 
useful for studying HIV-1 evolution with respect to drug and 
vaccine development. In addition, embodiments of the assay 
may provide a novel phenotypic test that can measure the 
rate at which HIV-1 is mutating. Additional embodiments, 
objects and advantages of the invention will become more 
fully apparent in view of the following detailed description 
an in conjunction with the accompanying drawings. 
[0015] FIG. 1: depicts an HIV-1 vector and flow chart for 
an embodiment of the inventive mutation assay. The HIV-1 
vector, pNL4-3lHcass, is shown at the top. Step 1: The 
vector is stably transfected into naive 143B cells. The cells 
are placed under selection with hygromycin B (Hyg) and 
cloned. Step 2: The 143B cell clones containing an inte­
grated HIV-1 vector are transiently transfected with HIV-1 
helper plasmids to produce vector virus. Step 3: Vector virus 
is used to infect fresh 143B cells. The cells are placed under 
selection with Hyg and cloned. Step 4: The 143B cell clones 
containing an integrated HIV-1 vector are transiently trans­
fected with HIV-1 helper plasmids to produce vector virus 
(same as step 2 except cells are infected, not transfected). 
Step 5: Vector virus is used to infect fresh 143B cells. Step 
6: Parallel infections are placed under selection with Hyg 
alone and Hyg plus BudR. Viral titers are calculated by 
counting the number of drug resistant colonies. The forward 
mutation frequency is calculated as shown. Cells are cloned 
for further analysis. 
[0016] FIG. 2: depicts an analysis of the Initiator Clones 
(ICs). (A) Agarose gel showing PCR results performed on 
genomic DNA ofiCs 1-6 and genomic DNA of 143B cells. 
The 1.6 kb band is specific for the HIV-1 vector sequence 
spanning CMV through TK. Lane M is a 1 kb marker. The 
predicted 1.6 kb PCR product was detected in all ICs but not 
in 143B genomic DNA, as expected. (B) Southern blot 
analysis of ICs 1-5. Lane C represents the 143B genomic 
DNA negative control. A high molecular weight marker was 
included on the gel with sizes listed on the left side. Only 
one band was detected for each IC, indicating one provirus 
per cell. In addition, the bands for each IC were different 
sizes, indicating that the ICs were independent cell clones. 
[0017] FIG. 3: illustrates the mutation rate of HIV-1. The 
mutation rate for HIV-1 was measured from three indepen­
dent Initiator Cell clones (ICs ). The number of infections is 
listed inside the colunm for each IC. The error bars represent 
1 standard deviation from the mean. 
[0018] The following definitions will be useful to under­
stand the several embodiments of invention disclosed 
herein. 
[0019] "cis"-refers to the presence of genes on the same 
chromosome, viral genome, or molecule; cis-acting-used 
in reference to the controlling effect of a regulatory gene or 
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element on a gene present on the same chromosome, viral 
genome, or molecule. Promoters, which affect the synthesis 
of downstream mRNA are cis-acting control elements. 
[0020] Retrovirus-RNA viruses that utilize reverse tran­
scriptase (RT) during their replication cycle. Retroviral 
genomic RNA is converted into double-stranded DNA by 
RT. The double-stranded DNA form of the virus is capable 
ofbeing integrated into the chromosome of the infected cell; 
once integrated, it is referred to as a "provirus." The provirus 
serves as a template for RNA polymerase II and directs the 
expression of RNA molecules which encode the structural 
proteins and enzymes needed to produce new viral particles. 
At each end of the provirus are structures called "long 
terminal repeats" or "LTRs". The LTR contains numerous 
regulatory signals including a promoter. 
[0021] Lentivirus-a genus in the Retroviridae family of 
retroviruses that give rise to slowly developing disease. 
Diseases caused by these viruses are characterized by a long 
incubation period and protracted course. An important factor 
in the disease caused by these viruses is the high mutability 
of the viral genome, which, inter alia, results in the produc­
tion of mutants capable of evading the host immune 
response. Non-limiting examples employable in the present 
invention include HIV-1, HIV-2, visna-maedi virus, which 
causes encephalitis (visna) or pneumonia (maedi) in sheep, 
the caprine arthritis-encephalitis virus, which causes 
immune deficiency, arthritis, and encephalopathy in goats; 
equine infectious anemia virus, which causes autoimmune 
hemolytic anemia, and encephalopathy in horses; feline 
immunodeficiency virus (FIV), which causes immune defi­
ciency in cats; bovine immunodeficiency virus (BIV), which 
causes lymphadenopathy, lymphocytosis, and possibly cen­
tral nervous system infection in cattle; and simian immu­
nodeficiency virus (SIV), which cause immune deficiency 
and encephalopathy in sub-human primates. 
[0022] HIV (human immunodeficiency virus; including 
HIV-1, and HIV-2), the etiologic agent of the human 
acquired immune deficiency syndrome (AIDS). 
[0023] Gene-a DNA sequence that comprises control 
and coding sequences necessary for the production of a 
particular protein, polypeptide or precursor-any portion of 
the coding sequence so long as the desired enzymatic 
activity is retained. A unit of heredity. 
[0024] Mutant-a gene or gene product which displays 
modifications in sequence and or functional properties when 
compared to the wild-type gene or gene product. 
[0025] Replication defective-refers to a virus that is not 
capable of a complete, effective replication cycle such that 
infective virions are not produced. 
[0026] Provirus-used in reference to a virus that is inte­
grated into a host cell chromosome (or genome) and is 
transmitted from one cell generation to the next without 
causing lysis or destruction of the host cell. 
[0027] Selectable marker-a gene which encodes a pro­
tein with a function that allows for the identification of cells 
that have been transfected or transformed with the marker 
gene (for example, an enzyme that confers resistance to an 
antibiotic or drug upon the cell in which the selectable 
marker is expressed). A positive selective marker is a gene 
whose expression permits the cell to live in the presence of 
a selectable agent. The selectable agent is a compound that 
distinguishes cells that do not express the selectable marker, 
typically by killing them. Bacterial hygromycin B phospho­
transferase (hyg) that confers resistance to the antibiotic 
hygromycin B and the bacterial xanthine-guanine phospho­
ribosyl transferase gene (also referred to a the gpt gene) that 
confers the ability to grow in the presence of mycophenolic 
acid are examples. Other selectable markers negative in that 
their use kills cells that do express the protein encoded by 
the selectable marker and their use is typically in conjunc­
tion with a cell line that lacks the relevant activity. Examples 
of negative selectable markers include the thymidine kinase 
(tk) gene that is used in conjunction with TK-negative cells. 
It is understood that TK-negative means that the cell does 
not express a functional TK protein and does not necessarily 
mean an absolute absence. A person skilled in the art will 
appreciate that there are many manipulations and disable­
ments that may be undertaken to eliminate the expression of 
a functional form of the typically expressed protein. 
[0028] Vector-nucleic acid molecules that transfer 
nucleic acid segments from one cell to another. It is intended 
that any form of a vector may be encompassed by this 
definition. For example, vectors include but are not limited 
to: viral vectors; plasmids; transposons; and so on. 
[0029] Cassette-a fragment or segment of DNA contain­
ing a particular grouping of genetic elements and/or genes. 
A cassette can be removed and inserted into a vector or 
plasmid as a single functional unit. 
[0030] Transfection-the uptake, expression and/or incor­
poration of foreign DNA into eukaryotic cells. May be 
accomplished by a variety of means known or yet to be 
developed in the art. 
[0031] Transduction-refers to the delivery of genetic 
material using a viral or retroviral vector by means of 
infection rather than by transfection. In specific embodi­
ments, retroviral vectors are used to transduce eukaryotic 
cells. E.g. a gene carried by a retroviral vector can be 
transduced into a cell through infection and provirus inte­
gration. A transduced gene is one that has been introduced 
into the cell via lentiviral or vector virus infection and 
provirus integration. 
[0032] Stably transduced-refers to the introduction and 
integration of foreign DNA into the genome of the trans­
ducted cell. "Stable transductant" refers to a cell which has 
stably integrated foreign DNA into the genomic DNA. 
[0033] Transiently transduced-introduction of foreign 
DNA into a cell where the foreign DNA fails to integrate into 
the genome of the transducted cell. The foreign DNA may 
persist in the nucleus ofthe transducted cell for several days. 
During this time the foreign DNA is subject to the regulatory 
controls that govern the expression of endogenous genes in 
the chromosomes. 
[0034] Non-dividing cell-target and/or host cells that do 
not divide, e.g. neuronal cells. Embodiments of the present 
assay are not intended to be limited to non-dividing cells. 
[0035] Embodiments of the present inventive lentiviral­
based retrovirus vector and cell-based assay for measuring 
the mutation rate of retroviruses are described in detail 
below. 
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[0036] The inventive assay as exemplified herein will 
yield conservative measurements for mutation rates. First, 
the entire tk sequence (996 bp) is used in the calculation. 
Second, some mutant proviruses will have more than one 
mutation. Although every base in the tk gene is subject to a 
potential deletion or insertion, not every base is subject to a 
non-synonymous base change. For tk, the probability of 
whether a base substitution will result in an amino acid 
replacement is 74%. That is, if random mutations occurred 
throughout the gene, 737 out of the 996 base changes would 
result in an amino acid change, but not all amino acid 
substitutions would result in loss of function for TK. Amino 
acid substitutions that do not knock out TK function would 
be susceptible to selection by BudR and would not be 
detected in the assay. The inventors are not aware of any 
reports on saturation mutagenesis of tk. Therefore, a com­
prehensive catalog of inactivating tk mutations is not avail­
able. If the mutation rate in this study had been calculated 
using 737 instead of 996 bases for tk, then the mutation rate 
would be 3.0x10-5 /base/cycle. The decision to include all 
996 bases in the calculation considers all types ofmutations: 
deletions, insertions, and substitutions. Mutant proviruses 
were counted as one in the mutation rate calculation, even 
though some mutants contained multiple genetic alterations. 
Table 2, below, shows that there were 43 mutations among 
27 mutants screened. If the mutation rate was adjusted to 
account, for multiple mutations, then the rate would be 
3.5x10 mutations/base/cycle. Thus, as stated, the reported 
mutation rate is a conservative one and could be as much as 
1.6-fold higher. 
[0037] One embodiment ofthe inventive vector is directed 
to a lentivirus-based retroviral vector wherein the vector 
comprises: at least a portion of a lentivirus genome; a 
disrupted gag and a disrupted pol gene such that the vector 
is rendered replication-defective; a disrupted env gene; and 
a mutational cassette, wherein the mutational cassette com­
prises sequences encoding: a mutation target promoter 
sequence; a genomic source comprising a mutation target 
gene wherein there is a number of base pairs in the mutation 
target gene; an internal ribosome entry site for expression of 
a selectable marker gene; and a selectable marker gene. 
[0038] Retroviruses are a class of viruses that have a 
single stranded, positive sense RNA genome and replicate 
through a double-stranded DNA intermediate directed by the 
process ofreverse transcription (RT). The DNA intermediate 
is referred to as the provirus. The provirus integrates into the 
host cell genome, thereby becoming acquired genetic mate­
rial. HIV-1 is a lentivirus, which is a genus of retroviruses. 
Lentiviruses are unique retroviruses that possess the ability 
to replicate in quiescent cells as well as replicating cells. 
Lentiviruses are associated with immune deficiency and 
neurodegeneration of the host. Examples of other lentivi­
ruses include simian immunodeficiency virus (SIV), bovine 
immunodeficiency virus (BIV), and feline immunodefi­
ciency virus (FIV). 
[0039] A gene is "disrupted" if it is rendered incapable of 
expressing its functional polypeptide. It may be disrupted by 
completely deleting it or by removing its initiation codon, 
inserting stop codons or base pairs to force a frameshift. One 
skilled in the art will appreciate that there are many effective 
means to disrupt a gene. In a specific embodiment the vector 
is replication deficient but transduction- and infection-com­
petent. 
[0040] In another specific embodiment the lentivirus 
genome is selected from the group consisting of human 
immunodeficiency virus type 1 (HIV-1 ), human immunode­
ficiency virus type 2, feline immunodeficiency virus, simian 
immunodeficiency virus, visna-maedi virus, caprine arthri­
tis-encephalitis virus, equine infectious anemia virus, and 
bovine immunodeficiency virus. In a very specific embodi­
ment the lentivirus genome comprises HIV-1. In certain 
embodiments the genome may comprise a hybrid of the 
aforementioned lentivirus genomes. 
[0041] In one aspect of the retrovirus vector the selectable 
marker comprises a positive selectable marker. In a further 
aspect the selectable marker comprises an antibiotic or drug 
resistance gene. In a very specific aspect, the internal ribo­
somal entry site promotes translation of the selectable 
marker and the selectable marker comprises a hygromycin B 
resistance gene. One skilled in the art will appreciate that the 
choice of promoter depends upon which drug resistance 
gene is employed as the selectable marker and that many 
means are commonly known in the art that suggest or 
determine an appropriate selection. 
[0042] In specific embodiments the number of base pairs 
in the mutation target gene is greater than 300 base pairs. A 
greater number of base pairs increases the size of the 
mutational target and, therefore, increases the statistical 
reliability and validity of the results. In more specific 
embodiments the number ofbase pairs in the mutation target 
gene is greater than 500 base pairs, and in a very specific 
embodiment the number of base pairs in the mutation target 
gene is greater than 700 base pairs. In a particular embodi­
ment the mutation target comprises a thymidine kinase gene 
that comprises about 1000 base pairs. In one embodiment 
the genomic source comprising a mutation target gene 
comprises a human herpes virus type 1 gene. 
[0043] Promoters are used to enhance or increase the 
expression of genes in the retrovirus vector. A promoter is a 
regulatory element that facilitates the initiation of transcrip­
tion of an operably linked coding region. The selection of a 
particular promoter depends on what cell type is to be used 
to express a protein, polypeptide or enzyme of interest. In 
one particular embodiment the mutation target promoter 
comprises a human cytomegalovirus (CMV) promoter and 
the mutation target comprises a thymidine kinase (tk) gene. 
[0044] Another embodiment of the invention is directed to 
a cell comprising the present lentivirus-based retroviral 
vector. The cell may comprise any cell which the vector is 
capable of infecting. Generally speaking, it will be a eukary­
otic cell, preferably a vertebrate cell, more preferably a cell 
of a mammal. The cell may be a dividing or non-dividing 
cell. Non-limiting examples of non-dividing cells include 
neuronal cells and astrocytes. Non-limiting examples of 
dividing cells include hematopoietic stem cells, muscle 
cells, white blood cells, spleen cells, liver cells, epithelial 
cells and eye cells. In one embodiment the cell of interest is 
negative for the mutation target gene. It is appreciated by 
those skilled in the art that "negative" in this context does 
not necessarily mean it is not present, but that it is disabled 
or disrupted to a degree that prevents the expression of a 
functional expression product. The inventors contemplate 
that expression product functioning may even be suppressed 
by an agent such as a drug or other compound. In a particular 
embodiment where the mutation target gene is thymidine 
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kinase, the cells comprise 143B cells. In one particul~r 
embodiment the cell is a dividing or non-dividing eukaryot1c 
cell. 
[0045] Another embodiment of the present invention pro­
vides an assay for determining a mutation frequency and a 
mutation rate of a retrovirus. The assay comprises: a) 
constructing the vector described above; b) stably transfect­
ing cells from a cell culture with the vector from (a) wherein 
the cell culture is negative for the mutation target gene; c) 
placing the cells under selection with a medium selectable 
for the selectable marker to produce a quantity of cell clones 
which contain an integrated vector; d) transiently transfect­
ing the quantity of cell clones with a set of helper plasmids 
to produce a vector virus, wherein the set ofhelper plasmids 
contain a complement of structural genes which permit 
replication; e) infecting naive cells from a cell culture ":ith 
the vector virus; f) placing the cells from (e) under selection 
with the medium selectable for the selectable marker; g) 
cloning the cells from (f) to produce a quantity ofcell clones, 
wherein each of the quantity of cell clones is designated as 
an Initiator Clone; h) confirming that the mutation target 
gene is functional in each Initiator Clone (IC) and, option­
ally, sequencing the mutation target gene for later compari­
son to mutation target genes which have undergone a cycle 
of replication; i) transiently transfecting the ICs with a set of 
helper plasmids to produce a vector virus; j) infecting naive 
cells from a target cell culture with the vector virus from (i) 
to produce a quantity of infected target cells; k) placing a 
first portion of the quantity of infected target cells under 
selection with the medium selectable for the selectable 
marker and a substantially similar second portion of the 
quantity of infected target cells under selection with the 
medium selectable for the selectable marker plus a selective 
medium for the mutation target gene; and I) determining a 
viral titer for the first portion and a viral titer for the second 
portion by counting drug-resistant quantities, wherein the 
mutation frequency is calculated by dividing the viral titer of 
the second portion by the viral titer of the first portion, and 
the mutation rate is calculated by dividing the mutation 
frequency by the number ofbase pairs in the mutation ta:get 
gene. In one embodiment, the assay further compnses 
providing a negative control group, wherein a quantity of 
naive cells from the cell culture is left uninfected and placed 
under selection with the medium selectable for the selectable 
marker plus a medium selectable for the mutation target 
gene. 
[0046] In more specific embodiments the retrovirus is 
selected from the group consisting of human immunodefi­
ciency virus type 1, human immunodeficiency virus type 2, 
feline immunodeficiency virus, simian immunodeficiency 
virus, visna-maedi virus, caprine arthritis-encephalitis virus, 
equine infectious anemia virus, and bovine immunodefi­
ciency virus. In a very specific embodiment the retrovirus is 
human immunodeficiency virus type 1. 
[0047] In further specific embodiments the selectable 
marker gene comprises an antibiotic or drug resistance gene 
and the medium selectable for the selectable marker com­
prises the corresponding antibiotic or drug. In one aspect the 
selectable marker gene comprises a hygromycin B resistance 
gene and the medium selectable for the selectable marker 
comprises hygromycin B. 
[0048] In additional embodiments the mutation target 
gene is a thymine kinase gene and the medium selectable for 
the mutation target gene comprises bromodeoxyuridine, 
gancyclivir, acyclivir, or HAT (hypoxanthine+aminopterin+ 
thymine). In a very specific embodiment the medium select­
able for the mutation target gene comprises bromodeoxyuri­
dine. 
[0049] In one aspect the cell culture comprises 143B cells. 
The 143B cell culture is a cell line available from the 
American Type Culture Collection, Manassas, Va. This cell 
line is a derivative of the human osteosarcoma cell line, 
HOS, and is negative for thymidine kinase (TK) function. 
[0050] The following descriptions and examples of the 
various embodiments of the invention have been presented 
for the purposes of illustration and are not intended to be 
exhaustive or to limit the invention to the precise form 
disclosed. Many alternatives, modifications and variations 
will be apparent to those skilled in the art. Accordingly, this 
invention is intended to embrace all alternatives, modifica­
tions and variations that are discussed and exemplified 
herein, and others that fall within the spirit and broad scope 
of the claims. 
EXAMPLES 
[0051] With respect to all the examples disclosed herein, 
the full-length HIV-1 genome that served as the basis for the 
HIV-1 vector (FIG. 1, top) and the p83-10 plasmid that 
contains the 3' half of HIV-1NL4 _3 were obtained through the 
AIDS Research and Reference Reagent Program, Division 
of AIDS, NIAID, NIH: pNL4-3. The helper plasmids, 
pCMVllR8.2 and pMD.G, were generously provided from 
the University of Geneva, Switzerland. Plasmid pCM­
VAR8.2 encodes structural proteins Gag and Pol, in addition 
to all of the HIV-1 accessory proteins. This Gag-Pol helper 
expresses sequences derived from both the HXB2J? and 
NILA-3 strains of HIV-1. However, the reverse transcnptase 
portion of pCMV llR8.2 was derived completely from 
NL4-3 (accession no. M19921 ). The pMD.G helper plasmid 
expresses G glycoprotein of vesicular stomatitis virus 
(VSV.G) and confers broad tropism via pseudotyping of the 
HIV-1 vector virus. Both of the helper plasmids express 
genes from heterologous promoters. The piREShyg2 plas­
mid was purchased from Clontech, a division of BD Bio­
sciences, Palo Alto, Calif. The gene for thymidine kinase 
(tk) was cloned from plasmid pKOS 17B2, obtained from 
Harvard Medical School, Boston, Mass. 
[0052] General molecular biology procedures, includiJ_Ig 
restriction enzyme digestion, agarose gel electrophoresis, 
DNA ligation, and bacterial transformation were performed 
using standard published procedures (see Ausubel et a!. 
"Current Protocols in Molecular Biology, John Wiley & 
Sons (1995) and Sambrook et a!. "Molecular Cloning: a 
laboratory manual" Cold Spring Harbor Laboratory, NY, 
(1989), incorporated herein by reference). 
[0053] All enzymes were purchased from New England 
Biolabs, Inc., Beverly, Mass., unless otherwise noted. 
Example 1 
[0054] This example illustrates the difference in the muta­
tion rate derived from employment of an embodiment of the 
inventive assay wherein HIV-1 is the retrovirus measured, 
and that derived from the reference Mansky in vivo assay on 
HIV-1. 
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[0055] The average mutation rate derived from the present 
assay is 1.6-fold lower than the rate reported by Mansky and 
Temin (1995) using the indirect in vivo assay for HIV-1 
(Table 3). Mansky's average rate was 3.5x1o-s mutations/ 
base/cycle. As shown in Table 3, Mansky's rate was based 
on lower numbers of mutants detected (specifically, 9.2-fold 
lower). Most likely, the lower frequency was due to the 
difference in the sizes ofthe mutational target sequences; the 
Mansky assay uses the lacZa peptide sequence, which is 3.6 
times smaller than the tk sequence used in the practice ofthis 
embodiment of the invention. The number of viruses 
screened cannot be directly compared because this number 
is unknown for the Mansky assay. A total number of 15,930 
viruses were screened in this example, while a total number 
of 8,678 bacterial colonies were screened in the Mansky 
assay. It is unlikely that each bacterial colony in the Mansky 
assay corresponds to an independent proviral sequence 
because cell colonies, each containing numerous cells, were 
pooled in the final step. 
[0056] This last point may explain why differences were 
found in the types of mutations observed in the present 
example versus Mansky assays (Table 2). In both assays, the 
majority of mutations were base substitutions. However, 
there were significantly less G---;.A transitions observed in 
the present example as compared to the Mansky assay 
(p=0.04). There were significantly more insertions observed 
in the present example as compared to the Mansky assay 
(p=0.02). There were significantly less single nucleotide 
deletions observed in the present example as compared to 
the Mansky assay (p=0.02). Lastly, there were significantly 
less transition mutations, and conversely more transversion 
mutations, observed in the present assay as compared to the 
Mansky assay (p=0.01). Frequencies were used in a one­
tailed Fisher's exact test to determine the statistical signifi­
cance with an alpha level of 0.05. For some categories of 
mutants, the numbers were too small for statistical analyses. 
Example 2 
[0057] This example illustrates construction of an HIV-1 
vector, named pNL4-3lHcass. 
[0058] A replication-defective HIV-1 vector was con­
structed based on the NL4-3 strain of HIV-1 (FIG. 1, top). 
The vector contains all of the cis-acting sequences necessary 
for replication, plus a complete set of intact accessory genes 
for HIV-1. Deletions were made in the gag, pol, and env 
genes to render the vector replication defective. Structural 
gene products, Gag, Pol, and Env, were supplied in trans by 
helper plasmids. In place of env, a mutational cassette was 
inserted that contained the human CMV promoter driving 
expression of tk, which provided the mutational target 
sequence for the assay. A functional tk gene renders cells 
resistant to medium containing HAT and susceptible to 
medium containing BrdU. An IRES sequence following tk 
allowed for expression of hyg, which provided a selectable 
marker via resistance to the antibiotic hygromycin B. 
[0059] The final HIV-1 vector, named pNL4-3lHcass, was 
verified by restriction enzyme analysis, sequencing, and 
phenotypic testing in 143B cells. All plasmid constructs 
leading up to the final vector were digested with restriction 
enzymes to verify the cloning process. The final vector was 
digested with six restriction enzymes (Aft II, Hind III, Kpn 
I, Pst I, Sac I, and Xnm I) and showed only bands of the 
predicted sizes, indicating that no major rearrangements, 
insertions, or deletions had occurred during the cloning 
process (data not shown). Sequencing revealed that the tk 
gene had no mutational defects. The final vector was trans­
fected into naive 143B cells, which are negative for TK 
function. The transfected cells were resistant to medium 
containing HAT and susceptible to medium containing 
BrdU, indicating that tk was functional. The transfected cells 
were also resistant to medium containing hygromycin B, 
indicating that hyg was functional. Finally, transfection of 
naive 143B cells with pNL4-3lHcass plus helper plasmids 
yielded virus, as indicated by successful transduction of the 
tk and hyg genes into fresh 143B cells. 
[0060] To create the pNL4-3lHcass vector (FIG. 1, top), 
deletions were made in the gag, pol, and env genes of 
pNL4-3, and a mutational cassette was inserted at the 
location of the env deletion. The deletion in gag-pol (cor­
responding to nucleotides 1340-3716 of the original NL4-3 
sequence, accession no. M19921) was created by digesting 
pNL4-3 with Swa I and purifYing the 12,503 bp fragment, 
which contained the plasmid backbone and the gag-pol­
deleted HIV-1 genome. The fragment was isolated using the 
Qiaquick Gel Extraction Kit (Qiagen, Valencia, Calif.) and 
ligated with T 4 DNA ligase. This intermediate construct was 
named pNL4-3llswa. 
[0061] The deletion in env (corresponding to nucleotides 
6401-7252 of the original NL4-3 sequence, accession no. 
M19921) was created in p83-1 0 ( 6,253 bp ), which contains 
the 3' half of the HIV-1 genome. Working with the 3' half of 
the HIV-1 genome allowed the use of restriction enzymes 
that were not unique in the full-length pNL4-3 plasmid. 
Plasmid p83-10 was digested with Nde I and Nhe I; the 
5,402 bp fragment, which contained the plasmid backbone 
and the env-deleted 3' half of HIV-1, was isolated by using 
the Qiaquick Gel Extraction Kit (Qiagen). This fragment 
was ligated with complementary oligonucleotides that 
inserted a multiple cloning site (MCS), creating intermediate 
construct p83-10MCS. The sequences of the oligonucle­
otides are as follows: MCS1 5'-TAT GGG CGC GCC ACG 
CGT CCC GGG G-3' and MCS2 5'-GCT AGC CCC GGG 
ACG CGT GGC GCG CCC ATA TG-3'. Restriction 
enzymes Sal I and Xho I were used to isolate a fragment 
from p83-10MCS that contained the env deletion. This 
fragment was then used to replace the corresponding frag­
ment in pNL4-3llswa that contained the intact env sequence. 
These cloning steps created intermediate construct pNL4­
3ll. 
[0062] The mutational cassette was created by using 
piREShyg2 from Clontech. The piREShyg2 plasmid is a 
bi-cistronic expression vector that expresses a gene of 
interest (tk, in this case) from the human cytomegalovirus 
(CMV) promoter. An internal ribosome entry site (IRES) 
allows for expression of the second gene, hygromycin 
phosphotransferase (hyg), which provided a selectable 
marker via resistance to the antibiotic hygromycin B. The tk 
sequence was amplified by polymerase chain reaction (PCR) 
from plasmid pKOS 17B2 using a set of primers containing 
BsrG I and BsiWI sites at 5' and 3' ends, respectively; tk was 
inserted into the MCS of piREShyg2 using these sites after 
intermediary cloning in a TOPO TA vector (Invitrogen, 
Carlsbad, Calif.), creating intermediate construct 
pTKIREShyg. The sequence encompassing the CMV pro­
moter, tk, IRES, and hyg was then amplified from 
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pTKIREShyg using a set of primers containing Mlu I and 
Nhe I sites at 5' and 3' ends, respectively. Following inter­
mediary cloning in a TOPO TA vector, these restriction sites 
were used to insert the CMV-tk-IRES-hyg mutational cas­
sette into pNL4-3ll. to create the final vector, pNL4-3ll.+cass. 
[0063] For cloning into the mutational cassette, the tk gene 
was amplified using Taq DNA polymerase in a 100-f.ll 
reaction, according to the manufacturer's protocol (Invitro­
gen). Twenty-five nanograms of plasmid pKOS17B2 was 
used in the reaction, along with 20 pmol of each of the 
following primers: TK1 5'-GCT ATG TAC AGC CAC CAT 
GCC CAC GCT ACT GCG GGT-3' and TK2 5'-GTA CCG 
TAC GTC AGT TAG CCT CCC CCA TCT-3'. The TK1 
primer encodes a BsrG I site near the 5' end followed by a 
Kozak sequence. The TK2 primer encodes the 3' end of tk, 
followed by a BsiWI site. Twenty-five cycles of the follow­
ing program were performed: 15 sec. at 94° C., 15 sec. at 60° 
C., and 1 min. at no C. Taq DNA polymerase was added to 
the reaction after an initial heating step at 94 o C. for 5 min, 
and a final extension step was performed at 72° C. for 10 
mm. 
[0064] For cloning into the HIV-1 vector, the CMV-tk­
IRES-tyg mutational cassette was amplified using Pfu­
Turbo® polymerase (Stratagene, La Jolla, Calif.) in a 50-f.ll 
reaction, according to the manufacturer's protocol. Twenty­
five nanograms of plasmid pTKIREShyg were used in the 
reaction, along with 10 pmol of each of the following 
primers: CMVCAS 1 5'-GAT CAC GCG TCG CGT TAC 
ATA ACT TAC GGT A-3' and CMVCAS 2 5'-GTC AGC 
TAG CTT CCT TTG CCC TCG GAC GAG-3'. CMVCAS 
1 encodes an Mlu I restriction enzyme site prior to the CMV 
promoter sequence, and CMVCAS 2 encodes the 3' end of 
hyg, followed by a Nhe I restriction enzyme site. Twenty­
five cycles of the following program were performed: 1 min. 
at 95° C., 1 min. at 58° C., and 4 min. at no C. An initial 
heating step at 95° C. for 3 min. and a final extension step 
at no C. for 10 min. were performed. 
Example 3 
[0065] The following example illustrates utilization ofone 
embodiment of the assay to determine the mutation rate of 
HV-1. 
[0066] The mutation rate assay for this example is outlined 
in FIG. 1. Serial dilutions of HIV-1 vector DNA were 
transfected into 143B cells, which were placed in medium 
containing hygromycin B to select for resistant cells. Hygro­
mycin B resistant cells were cloned by picking well-isolated 
colonies from plates receiving the highest dilutions of DNA 
(step 1, FIG. 1). In order to remove mutations that may have 
occurred during transfection and to improve the probability 
for isolating clones that contained only one vector per cell, 
a subsequent infection step was performed. The 143B clones 
containing the HIV-1 vector were transiently transfected 
with HIV-1 helper plasmids for transient production of 
vector virus (step 2, FIG. 1). Serial dilutions of this virus 
were then used to infect fresh 143B cells, which were placed 
in medium containing hygromycin B to select for resistant 
cells. Hygromycin B-resistant cells were cloned by picking 
well-isolated colonies from plates receiving the highest 
dilutions of virus (step 3, FIG. 1). The resulting cell clones 
were called the Initiator Cells (ICs) and served as the basis 
for the single cycle of replication assay. 
[0067] The ICs generated in step 3, FIG. 1, were rigor­
ously characterized by molecular and phenotypic analyses to 
ensure a successful and accurate mutation rate assay. Poly­
merase chain reaction was performed with the genomic 
DNA of each IC to detect the presence of provirus using 
primers specific for the sequence that spans CMV through 
tk. The same PCR was performed with the genomic DNA of 
naive 143B cells as a negative control. The predicted PCR 
product of 1,600 bp in length was detected in all ICs and not 
in the naive 143B cells (FIG. 2A). A Southern blot analysis 
was performed on the genomic DNA of each IC to ensure 
that each IC contained only one HIV-1 vector sequence. The 
cellular DNA was digested with EcoR I, which generated a 
3' fragment of the viral genome with adjacent cellular DNA. 
A radio labeled probe specific for this 3' region of the virus 
was used to detect a single band in each IC (FIG. 2B). The 
bands for each IC were different sizes, confirming that each 
IC was an independent cell clone (FIG. 2B). Each IC was 
grown in medium containing BrdU for a two-week period. 
The BrdU selection resulted in the complete death of ICs 2, 
3, and 4, indicating functional tk expression in these cell 
clones. These ICs were chosen for the assay and their tk 
genes were sequenced and found to be identical to the tk 
sequence from the original pNL4-3ll.+cass vector. Transient 
transfection of helper plasmids into the ICs produced viral 
titers in the range of 102 to 104 cfu/ml, which provided a 
sufficient number of mutants from a practical number of 
infections. 
[0068] Once the ICs were established, they were tran­
siently transfected with the HIV-1 helper plasmids to gen­
erate virus for the single cycle ofreplication (step 4, 628FIG. 
1). HIV-1 vector virus was harvested from the ICs and used 
to infect fresh 143B cells (step 5, FIG. 1). Steps 4 and 5 
constitute the single cycle of replication (from provirus to 
provirus, IC to target cell). Finally, parallel sets of infections 
were placed under two types of drug selection: hygromycin 
B plus BrdU (Hyg+BrdU) and hygromycin B alone (Hyg) 
(step 6, FIG. 1). Mock infections, performed in parallel as a 
negative control, showed no colony formation under the 
Hyg+BrdU selection. Viral titers were determined by count­
ing the number of drug-resistant colonies in the linear range 
of the titration. The Hyg+BrdU titer revealed the number of 
mutants, while the Hyg titer revealed the number of viruses 
screened. The mutation frequency was calculated by divid­
ing the total number ofmutants detected by the total number 
of viruses screened (final step, FIG. 1 and Table 1 ). 
[0069] For verification of the Initiator Clones, the CMV-tk 
region (1,600 bp) was amplified from genomic DNA (from 
step 3, FIG. 1) using Taq DNA polymerase (Invitrogen) in 
a 100-f.ll reaction, according to the manufacturer's protocol. 
Two hundred nanograms of genomic DNA were used in the 
reaction, along with 20 pmol of primers CMVCAS 1 and 
TK2. Twenty-five cycles of the following program were 
performed: 30 sec. at 94° C., 30 sec. at 58° C., and 2 min. 
at no C. Taq DNA polymerase was added to the reaction 
after an initial heating step at 94 o C. for 5 min, and a final 
extension step was performed at 72° C. for 10 min. 
[0070] The DNeasy Tissue Kit (Qiagen) was used to 
isolate the genomic DNA from cultured cells per manufac­
turer's protocol. 
[0071] The 143B cell line was purchased from the Ameri­
can Type Culture Collection, Manassas, Va. This cell line is 
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a derivative of the human osteosarcoma cell line, HOS, and 
is negative for thymidine kinase (TK) function. The cells 
were maintained in minimal essential medium (MEM) with 
Earl's BSS (Mediumtech, Herndon, Va.) supplemented with 
10% fetal bovine serum, 2 mM L-glutamine, 100 U/ml 
penicillin, 100 f.tg/ml streptomycin (Invitrogen). Cells were 
passaged twice per week and were grown at 37° C. and 5% 
C02 . 
[0072] For selection of drug resistant colonies, cells were 
cultured for two weeks in medium containing the appropri­
ate agent. The final concentration for each agent was deter­
mined empirically using 143B cells. The antibiotic hygro­
mycin B (Invitrogen) was used at 0.27 mg/ml. The 
nucleoside analog bromodeoxyuridine (BrdU; Sigma-Ald­
rich Co., St. Louis, Mo.) was used at 0.12 mg/ml. The final 
concentrations of hypoxanthine, aminopterin, and thymine 
(HATi; Sigma-Aldrich) were 5x10-5 M, 2x10-7 M, and 
8x10 M, respectively. 
[0073] Cells were cloned by choosing well-isolated colo­
nies from plates receiving the highest dilutions of DNA or 
virus (steps 1 and 3, respectively, FIG. 1) or plates in the 
linear range of the titration (step 6, FIG. 1). A sterile 5-mm 
Bel-Art cloning disk (Fisher Scientific, Pittsburgh, Pa.) 
treated with trypsin-EDTA (0.25%, Invitrogen) was placed 
onto the colony, incubated for 3'h min., and transferred into 
the well of a 24-well plate containing medium. 
[0074] Stable and transient transfections (steps 1 and 2, 
FIG. 1) were performed by the dimethyl sulfoxide (DMSO)/ 
polybrene method. For step 1, serial 5-fold dilutions of 
DNA, starting with 5 flg, were transfected onto 143B cells 
plated at 2x105 cells/60 mm dish 24 hours pre-infection. For 
step 2, 9 flg of pCMVllR8.2 and 3 flg of pMD.G were 
transfected onto cell clones (isolated from step 1) plated at 
2x105 cells/60-mm dish, 24 hours pre-transfetion. After 6 
hours of incubation with DNA, cells were shocked with 25% 
DMSO for 3'h min. and were placed in appropriate selective 
medium at 24 hours post-transfection. 
[0075] Transient transfection (step 4, FIG. 1) was per­
formed using the LipofectAMINE™ 2000 per manufactur­
er's protocol (Invitrogen). Three micrograms of 
pCMVllR8.2 and one microgram of pMD.G were trans­
fected onto ICs (isolated from step 3) plated at 2x105 
cells/60-mm dish, 24 hours pre-transfection. The medium 
was replaced 24 hours after transfection. 
[0076] Virus stock was harvested at 62 hours post-trans­
fection by centrifugation of cell supernatant fluid at 1430xg 
for 10 min. at room temperature in sealed GH 3.8 rotor 
buckets of a Beckman GS-6R tabletop centrifuge to remove 
any detached cells. The 62-hour time point was chosen 
empirically based on transduction efficiencies with the 
HIV-1 based vector pHR'CMV-GFP, which encodes the 
gene for green fluorescent protein, and helper plasmids 
pCMVllR8.2 and pMD.G. 
[0077] Infections were performed with fresh virus stock 
and polybrene (8 flg/ml) in a final volume of 2 ml with cells 
plated 24 hours pre-infection at a density of 2x1 05 cells/60­
mm dish. Cells were incubated with virus for 3 hours, at 
which time the viral supernatant was replaced with fresh 
medium. At 24 hours post-infection, the medium was 
replaced with fresh medium containing the appropriate 
selective agent. Media containing the appropriate selective 
agents were replaced twice a week for two weeks. Serial 
10-fold dilutions of virus were used to determine viral titers, 
which were measured by counting the number of drug-
resistant colonies in the linear range of the titration. Viral 
titers are reported as the number of colony forming units per 
milliliter ( cfu/ml). 
[0078] Mutation frequencies and rates were calculated 
using simple mathematical formulas. The mutation fre­
quency was calculated by dividing the total number of 
mutants by the total number ofviruses (Hyg+BrdU titer/Hyg 
titer; FIG. 1 and Table 1). The mutation rate was calculated 
by dividing the mutation frequency by the number of bases 
in tk (996 bases). 
Example 4 
[0079] This example illustrates determination of mutation 
types in the mutational target gene subsequent to the assay. 
[0080] For sequencing of the final mutants, the tk gene 
was amplified from genomic DNA isolated from the Target 
Cells (final step, FIG. 1) using Accuprime™ Taq DNA 
polymerase (Invitrogen) in a 1 0-f.ll reaction, according to the 
manufacturer's protocol. Three hundred nanograms of 
genomic DNA were used in the reaction, along with 20 pmol 
of each of the following primers: TKA1 5'-TCA CTA TAG 
GGA GAC CCA AGC 3' and TKA2 5'-CCC TCG CAG 
ACA GCG AAT TAA-3'. Twenty-five cycles of the follow­
ing program were performed: 45 sec. at 94 o C., 45 sec. at 58° 
C., and 1 min. at no C. An initial heating step at 94° C. for 
2 min. and a final extension step at no C. for 10 min. were 
performed. Primers and excess nucleotides were inactivated 
by adding 1.9 U Exonuclease I and 0.38 U Shrimp Alkaline 
Phosphatase (Amersham Biosciences, Piscataway, N.J.) to 
the PCR reaction. The final reaction volume was adjusted to 
12.5 fll using ultra pure water. The reaction was incubated at 
37° C. for 30 min., and enzymes were heat inactivated at 80° 
C. for 20 min. 
[0081] All PCR reactions were performed on a Peltier 
Thermal Cycler 200 (MJ Research, Reno, Nev.) with the 
exception of the final amplification of tk from the Target 
Cells, which was performed on a GeneAmp PCR System 
9600 (Applied Biosystems, Foster City, Calif.). 
[0082] Southern blotting was performed using standard 
published procedures (Ausubel and Sambrook, supra). 
Briefly, 15 flg of genomic DNA was digested with EcoR I 
and separated in a 1% agarose gel. DNA was transferred via 
capillary action onto a Hybond-N+ membrane (Amersham). 
The membrane was hybridized with a radiolabeled fragment 
complementary to the 3' halfof the HIV-1 genome (a 422-bp 
BamH I to Xho I fragment, specific for the Rev-responsive 
element and tat gene). The fragment was labeled using the 
Rediprime™ II DNA Labeling System and a-32P dCTP per 
manufacturer's protocol (Amersham). The Qiaquick Nucle­
otide Removal Kit (Qiagen) was used to remove the excess 
dNTPs from the radio labeled probe. The radioactive content 
of the probe was quantified using a scintillation analyzer. 
Results were visualized by autoradiography using Kodak 
X-OMAT AR2 film (Fisher Scientific). 
[0083] Purified PCR products were reduced to a concen­
tration of 50 ng/fll by centrifugation under vacuum, and 200 
ng of each sample was sent to Lark Technologies, Inc., 
Houston, Tex. for sequencing. The following two primers 
were used: FORWARD-TK 5'-TAC CTT ATG GGC AGC 
ATG ACC-3' and REVERSE-TK 5'-CTG CAG ATA CCG 
CAC CGT ATT-3'. The sequencing results were aligned and 
analyzed for non-synonymous base substitutions, insertions, 
and deletions using MacVector™ software version 6.5.3 
(Accelrys, San Diego, Calif.). 




[0084] This example compares the mutation rates calcu­
lated according to an embodiment of the present assay with 
calculations reported for a widely known assay that also 
employs tk as the mutational target. 
[0085] The overall mutation rate derived according to the 
present inventive assay for HIV-1 was slightly higher and 
the tk inactivation rate was slightly lower in comparison to 
an in vivo study on Moloney murine leukemia virus 
(MoMLV), in which tk was part of a larger mutational 
cassette. In the MoMLV study, an overall mutation rate of 
1.6x10-5/base/cycle and a tk inactivation rate of 3.0% per 
kbp were reported. One difference is the types of mutations 
observed. The majority of mutations detected in the muta­
tional target gene of the present assay were base substitu­
tions, while the majority of mutations in the MoMLV study 
were labeled as "gross rearrangements" (deletions, deletions 
with insertions, duplications, and complex hypermutations). 
The majority of gross rearrangements in the MoMLV study 
were found at locations corresponding to open regions of 
RNA: hairpin loops, internal loops, and bulges. This under­
scores the importance of sequence context in interpreting 
patterns of mutations. The different patterns of mutation 
observed between MoMLV (a y-retrovirus) and HIV-1 (a 
lentivirus) also emphasizes the caution that must be exer­
cised when extrapolating results from one retroviral genus to 
another. 
Examplre 6 
[0086] The following example illustrates calculation of 
the mutation rate. 
[0087] Mutation rates were calculated from 27 indepen­
dent infections from each IC (FIG. 3 and Table 1). Mock 
infections, performed in parallel as a negative control, 
showed no colony formation under Hyg+BrdU selection. 
The mutation rate was calculated by dividing the mutation 
frequency (Table 1) by the size of the tk sequence, which 
was 996 bases from start to stop codon. The average 
mutation rate for HIV-1 was 2.2x1o-s mutations/base/cycle 
of replication (Table 1). 
Example 7 
[0088] This example illustrates determination of the types 
of mutations that resulted in loss of TK function. 
[0089] Twenty-seven of 349 mutants were randomly 
selected for sequencing in order to determine the types of 
mutations that resulted in loss offunction for TK (Table 2). 
The majority of mutations (65%) were base substitutions 
with a preponderance of c~u (21%) and G~A (14%) 
mutations. One G~A and one c~A hypermutant were 
observed, as defined by nonconsecutive but repetitive sub­
stitution of adenosines. In this case, the hypermutation was 
not extensive; only two or three substitutions were observed 
in each hypennutant. Insertions were observed approxi­
mately twice as often as deletions (23% and 12%, respec­
tively). Among the insertions, a predominance of single 
adenosine additions was observed at a given time in an 
infected individual. Thus, such a hypermutaion could predict 
the future pattern of mutation and could assist in making 
treatment decisions, especially for newly infected people 
and those who are changing drugs due to treatment failure. 
TABLE 1 
IC2 IC3 IC4 Totals 
Number of mutants detected 142 53 154 349 
Number of viruses screened 5,265 3,375 7,290 15,930 
Mutation frequencya 2.7 1.6 2.1 2.2 
(x10-2 mutations/cycle) 
Mutation rateb 2.7 1.6 2.1 2.2 
(X 10-5 mutations/base/cycle) 
Mutation data for individual Initiator Clones (!C) 
aMutation frequency = Number of mutants detected/Number of viruses 
screened 




Tvoes of mutations observed 

No. of mutations observed (%) 

Type of mutationa Present Assay Mansky Assayb 
Substitutions 
c~u 







G ~ A hypermutantc 
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Deletion with Insertion 
5 (12) 10 (25) 
M,+15 0 _]_QL_ 
Total Mutations 
Total Mutants Screened 
43 (100) 
27 [26,892 bases] 
40 (100) 
38 [10,640 bases] 
aThe asterisk indicates statistically significant differences between the 





bMansky and Temn, 1995. 

cEach mutation cmmted separately toward the total number of mutations. 






Comparison of mutation data between assays 

Present Assay Mansky Assay" 

Number of mutants 349 
detected 
Number of viruses screened 15,930 8,678c 
Mutation frequencyd 2.2 4.4 
(x10-2 mutations/cycle) 
Mutation ratee 2.2 3.5 
(X 10-5 mutations/base/cycle) 
"Mansky and Temin, 1995 
blnterpreted from the nwnber of mutant bacterial colonies 
crnterpreted from the total number of bacterial colonies 
dMutation frequency = Nwnber of mutants detected/Nwnber of viruses 
screened 
eMutation rate = Mutation frequency/Number of bases in each target 
sequence 
1. A lentivirus-based retroviral vector wherein the vector 
comprises: at least a portion of a lentivirus genome; a 
disrupted gag and a disrupted pol gene such that the vector 
is rendered replication-defective; a disrupted env gene; and 
a mutational cassette, wherein the mutational cassette com­
prises sequences encoding: a mutation target promoter 
sequence; a genomic source comprising a mutation target 
gene wherein there is a number of base pairs in the mutation 
target gene; an internal ribosome entry site for expression of 
a selectable marker gene; and a selectable marker gene. 
2. The vector recited in claim 1 wherein the vector is 
transduction- and infection-competent. 
3. The vector recited in claim 1 wherein the lentivirus 
genome is selected from the group consisting of human 
immunodeficiency virus type 1, human immunodeficiency 
virus type 2, feline immunodeficiency virus, simian immu­
nodeficiency virus, visna-maedi virus, caprine arthritis-en­
cephalitis virus, equine infectious anemia virus, bovine 
immune deficiency virus, and hybrids thereof. 
4. The vector recited in claim 1 wherein the lentivirus 
genome comprises human immunodeficiency virus type 1. 
5. The vector recited in claim 1 wherein the selectable 
marker comprises a positive selectable marker. 
6. The vector recited in claim 1 wherein the selectable 
marker comprises a hygromycin B resistance gene. 
7. The vector recited in claim 1 wherein the selectable 
marker comprises a hygromycin B phosphotransferase gene. 
8. The vector recited in claim 1 wherein the mutation 
target gene comprises greater than 300 base pairs. 
9. The vector recited in claim 1 wherein the mutation 
target gene comprises greater than 500 base pairs. 
10. The vector recited in claim 1 wherein the mutation 
target gene comprises greater than 700 base pairs. 
11. The vector recited in claim 1 wherein the mutation 
target promoter gene comprises a human cytomegalovirus 
promoter, and the mutation target comprises a thymidine 
kinase gene. 
12. The vector recited in claim 1 wherein the genomic 
source comprising a mutation target gene comprises a 
human herpes virus type 1 gene. 
13. A cell comprising the lentivirus-based retroviral vec­
tor as recited in claim 1. 
14. The cell recited in claim 13 wherein the cell 1s a 
dividing or non-dividing eukaryotic cell. 
15. The cell recited in claim 14 wherein the cell 1s a 
dividing cell. 
16. The cell recited in claim 14 wherein the cell 1s a 
non-dividing cell. 
17. An assay for determining a mutation frequency and a 
mutation rate of a retrovirus comprising: 
a) constructing the vector recited in claim 1; 
b) stably transfecting cells from a cell culture with the 
vector from (a) 
c) placing the cells under selection with a medium select­
able for the selectable marker to produce a quantity of 
cell clones which contain an integrated vector; 
d) transiently transfecting the quantity of cell clones with 
a set of helper plasmids to produce a vector virus, 
wherein the set of helper plasmids contain a comple­
ment of structural genes which permit replication; 
e) infecting naive cells from a cell culture with the vector 
virus; 
f) placing the cells from (e) under selection with the 
medium selectable for the selectable marker; 
g) cloning the cells from (f) to produce a quantity of 
initiator cell clones, wherein each of the quantity ofcell 
clones is designated as an Initiator Clone (IC); 
h) confirming that the mutation target gene is functional 
in each IC and sequencing the mutation target gene for 
later comparison to mutation target genes which have 
undergone a cycle of replication; 
i) transiently transfecting the Initiator Clones with a set of 
helper plasmids to produce a vector virus; 
j) infecting naive cells from a target cell culture with the 
vector virus from (i) to produce a quantity of infected 
target cells; 
k) placing a first portion of the quantity of infected target 
cells under selection with the medium selectable for the 
selectable marker and a substantially similar second 
portion of the quantity of infected target cells under 
selection with the medium selectable for the selectable 
marker plus a selective medium for the mutation target 
gene; wherein a number of drug resistant colonies 
grows from the first and second portions, and 
I) determining a viral titer for the first portion and a viral 
titer for the second portion by counting the number of 
drug-resistant colonies; 
wherein the mutation frequency is calculated by dividing 
the viral titer of the second portion by the viral titer of 
the first portion, and the mutation rate is calculated by 
dividing the mutation frequency by the number of base 
pairs in the mutation target gene. 
18. The assay as recited in claim 17 wherein the cell 
culture is negative for the selectable marker. 
19. The assay as recited in claim 17 wherein the retrovirus 
is selected from the group consisting of human immunode­
ficiency virus type 1, human immunodeficiency virus type 2, 
feline immunodeficiency virus, simian immunodeficiency 
virus, visna-maedi virus, caprine arthritis-encephalitis virus, 
equine infectious anemia virus, and bovine immune defi­
ciency virus, and hybrids thereof. 
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20. The assay as recited in claim 17 wherein the retrovirus 
is human immunodeficiency virus type 1. 
21. The assay as recited in claim 17 wherein the selectable 
marker gene comprises a hygromycin B resistance gene and 
the medium selectable for the selectable marker comprises 
hygromycin B. 
22. The assay as recited in claim 21 wherein the hygro­
mycin B resistance gene comprises hygromycin B phospho­
transferase gene. 
23. The assay as recited in claim 17 wherein the mutation 
target gene is a thymidine kinase gene and the medium 
selectable for the mutation target gene comprises bromode­
oxyuridine or HAT. 
24. The assay as recited in claim 17 wherein the medium 
selectable for the mutation target gene comprises bromode­
oxyuridine. 
25. The assay as recited in claim 17 wherein the cell 
culture comprises 143B cells. 
26. The assay as recited in claim 17 wherein the assay 
further comprises providing a negative control group, 
wherein a quantity of naive cells from the target cell culture 
is left uninfected and placed under selection with a medium 
selectable for the selectable marker plus a medium select­
able for the mutation target gene. 
* * * * * 
